E-vapor company Ispire has reported a 26.9% year-on-year growth in its revenue for the third quarter of 2023, reaching $24.1 million, as per its 10-Q report submitted to the U.S. Securities and Exchange Commission (SEC) on May 15, 2023. Gross profit for the same period saw a 51.9% increase, hitting $4.5 million. Notably, Ispire's fiscal year ends on June 30th, not the traditional December 31st.
According to CFO Michael Wang, the firm anticipates a 58% to 98% sequential revenue growth from cannabis-related products in the fourth quarter. "We're focused on a multi-pronged strategy aimed at increasing the sales of our e-vapor products and developing CBD e-vapor products, with an emphasis on medical and recreational uses," Wang stated.
In Q3, Ispire's revenue from e-vapor products amounted to $16.5 million, while CBD-related vapor products contributed $7.6 million. The total operating costs grew 106.2% to $8 million, compared to $3.9 million in the same period of 2022. This led to a net loss of $3.1 million, a significant increase from the $1 million loss in Q3 2022.
Looking ahead, Ispire anticipates Q4 revenues from CBD vapor products to range from $12 million to $15 million, a 58% to 98% growth from Q3 2023. Ispire, which began marketing its CBD vapor products in mid-2020, is engaged in the research, design, commercialization, sales, promotion, and distribution of branded e-cigarettes and CBD vapor products. Its tobacco e-vapor products are sold under the brand name Aspire.
Thumbnail source: Ispire
*This article is an original article of 2FIRSTS Technology Co., Ltd. The copyright and license rights belong to the company. Any entity or individual shall make link and credit 2FIRSTS when taking actions to copy, reprint or distribute the original article. The company retains the right to pursue its legal responsibility.
